Phase 1 Study of HS-20152 in Healthy Participants

This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults. Secondary objectives include characterization of pharmacokinetics and pharmacodynamic effects on complement-related biomarkers.

NCT Number	NCT07503015
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Healthy Volunteers
Enrollment	32 participants
Start Date	2026-04-22
Primary Completion	2027-01-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-31